Drug Profile
Immunoglobulin - Liminal BioSciences
Alternative Names: IVIG - Liminal BioSciencesLatest Information Update: 16 Jan 2022
Price :
$50
*
At a glance
- Originator NantPharma; ProMetic Life Sciences
- Developer Liminal BioSciences; NantPharma
- Class Immunoglobulin isotypes
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunodeficiency disorders
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-III for Immunodeficiency disorders (In adolescents, In children, In the elderly, Treatment-experienced, In adults) in USA (IV) (Liminal BioSciences pipeline, October 2021).
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences
- 22 Feb 2019 Immunogenicity data from a phase III trial in Immunodeficiency disorders presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2019)